Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milk Intranasal Therapy for neonates with post-hemorrhagic ventricular dilatation
NL-OMON58075Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial in Neonatal posthemorrhagic hydrocephalus (PHVD) and posthemorrhagic hydrocephalus (PHH), sponsored by University Medical Center Utrecht. Primary endpoints: Safety of intranasal maternal milk plasma, Dose-limiting toxicity and 2 more. Started Jan 2026; status: recruiting.
02
Conditions
Neonatal posthemorrhagic hydrocephalus (PHVD)posthemorrhagic hydrocephalus (PHH)
Beyond the preview
Go deeper on NL-OMON58075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58075.